Centessa Pharmaceuticals (CNTA) Stock Statistics & Valuation Metrics

Centessa Pharmaceuticals has a market cap or net worth of $3.56B. The enterprise value is $3.13B.

Centessa Pharmaceuticals has 146,075,740 shares outstanding. The number of shares has decreased by -2.65% in one year.

Centessa Pharmaceuticals’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -39.23%.

The current PE Ratio of Centessa Pharmaceuticals is ―. Centessa Pharmaceuticals’s PEG ratio is -0.26.

In the last 12 months, Centessa Pharmaceuticals had revenue of 0.00 and earned -235.76M in profits. Earnings per share was -2.06.

In the last 12 months, operating cash flow was -180.81M and capital expenditures -360.00K, giving a free cash flow of -181.17M billion.

Centessa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Centessa Pharmaceuticals upcoming earnings date is Mar 26, 2026, Before Open (Confirmed).

Centessa Pharmaceuticals as a current ratio of 9.25, with Debt / Equity ratio of 34.25%

In the past 12 months, Centessa Pharmaceuticals has paid 2.84M in taxes.

Centessa Pharmaceuticals EV to EBITDA ratio is -7.44, with an EV/FCF ratio of -11.62.

Centessa Pharmaceuticals has $246.21M in cash and marketable securities with $118.26M in debt, giving a net cash position of $127.95M billion.

Gross margin is 94.09%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Centessa Pharmaceuticals is $39.90, which is 11.43% higher than the current price. The consensus rating is Strong Buy